
Strategies for ADC Bioanalysis: Building for Complexity, Designing for the Future
Resolian’s Andy Xue on what makes ADC bioanalysis uniquely demanding, and how the team builds scalable, drug-tolerant methods across ADCs, PDCs, and AOCs.

Resolian’s Andy Xue on what makes ADC bioanalysis uniquely demanding, and how the team builds scalable, drug-tolerant methods across ADCs, PDCs, and AOCs.

Resolian’s Ashley Phillips on why LC-MS outperforms immunoassays for protein biomarkers, from isoform differentiation to drug-tolerant assay design.

Choosing a bioanalytical partner for biopharma startups? Follow these 5 proven criteria to protect your timeline, data quality, and regulatory readiness.

Running a global program? Here’s how to choose a bioanalytical CRO for global drug development, from lab footprint to phase-to-phase handoffs.

USP 665 and USP 1665 are now mandatory for pharma and biopharma manufacturers using plastic components. Learn what compliance requires and how Resolian’s E&L experts can help.

How do you evaluate a CRO beyond price? This guide covers technical capabilities, quality systems, geographical reach, and partnership factors that matter most.

Resolian works alongside drug developers as a trusted guide, delivering nitrosamine testing data to support confident risk decisions.

Proud to see Resolian’s permeability studies acknowledged in groundbreaking research published in the Journal of Medicinal Chemistry.

Resolian combines the Cytek Aurora Full Spectrum Profiling platform with 25+ years of flow cytometry expertise to deliver complete immune clarity and confident, regulatory‑ready decisions for cell & gene therapy programs.

Ensure inhalation product safety and compliance with Resolian’s advanced foreign particulate matter characterization and root cause analysis solutions.
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.